LXRX

LEXICON PHARMACEUTICALS, INC.

BS score 28.4LOWPHASE3 · mkt cap $745.7M · rev ttm $49.8M

drug hypothesis

sotagliflozin modulates SGLT1 and SGLT2 (sodium-glucose cotransporter types 1 and 2) to treat Type 1 diabetes with diabetic kidney disease (based on provided clinical trial data); also in development for hypertrophic cardiomyopathy and approved for heart failure.

moa:Dual inhibitor of SGLT1 and SGLT2 glucose transporters, leading to enhanced glycemic control through reduced glucose reabsorption in the kidneys and intestines

score breakdown

trial design7

base rate disconnect14

language red flags100

composite28.4

valuation analysis

market cap$745.7M

revenue ttm$49.8M

phasePHASE3

historical base rate30%

disconnect ratio0.5x

lead trialNCT06217302

meta

cik0001062822

first discovered2026-04-09

last updated2026-04-10

statusACTIVE

llm model—

extracted at2026-04-10

trial design

Randomized, quadruple, placebo-controlled Phase 3 trial enrolling 150 patients with type 1 diabetes and diabetic kidney disease; 3-year treatment period followed by 2-month wash-out period

primary endpoint:eGFR at the end of the wash-out period following the treatment period (End of the 2-month wash-out period following the 3-year treatment period)

claimed differentiation

Dual SGLT1/2 inhibition offers superior metabolic profile compared to SGLT2-selective inhibitors based on preclinical studies showing favorable phenotypes in mice lacking both targets

language red flags

Company uses three different brand names (INPEFA, ZYNQUISTA, sotagliflozin) for same molecule depending on indication, creating appearance of multiple products
Fast Track designation cited for pilavapadin but primary endpoint in Phase 2b was not statistically significant (p=0.11)
Post hoc analyses described as 'nominally significant' after failing primary endpoint
Vague timeline for catalysts - 'ongoing' with no specific dates
NOOH proceedings described as 'at our request' suggesting aggressive regulatory strategy
Third-party investigator-initiated study (STENO1) being relied upon for regulatory resubmission rather than company-sponsored trial

company-stated risks

Regulatory risk - FDA issued complete response letters in March 2019 and December 2024 for type 1 diabetes NDA
DKA (diabetic ketoacidosis) risk in type 1 diabetes population
Competition from SGLT2-selective inhibitors already approved for diabetes and heart failure
Need to demonstrate adequate safety data in patient exposure before NDA resubmission

upcoming catalysts

Ongoing; FDA indicated data could support review prior to completionSTENO1 study data completion to support NDA resubmission for type 1 diabetes
Not explicitly stated in filingSONATA-HCM Phase 3 trial readout for hypertrophic cardiomyopathy